EGFR (L718Q)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.L718Q
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Canertinib | 99.2% | 0.8% | 96.49 |
| 2 | Dacomitinib | 97.3% | 2.7% | 97.99 |
| 3 | Neratinib | 97.2% | 2.8% | 93.18 |
| 4 | Erlotinib | 90.8% | 9.2% | 99.75 |
| 5 | Mobocertinib | 88.4% | 11.6% | 97.22 |
| 6 | Lapatinib | 69.3% | 30.7% | 99.25 |
| 7 | Osimertinib | 61.1% | 38.9% | 97.24 |
| 8 | Lazertinib | 53.9% | 46.1% | 97.47 |
| 9 | Vandetanib | 51.8% | 48.2% | 95.74 |
| 10 | Ibrutinib | 50.9% | 49.1% | 94.74 |
| 11 | Fostamatinib | 31.5% | 68.5% | 96.74 |
| 12 | Imatinib | 28.4% | 71.6% | 99.00 |
| 13 | Ribociclib | 28.2% | 71.8% | 99.25 |
| 14 | Zanubrutinib | 22.7% | 77.3% | 98.24 |
| 15 | Defactinib | 22.6% | 77.4% | 92.68 |
| 16 | Trametinib | 17.6% | 82.4% | 99.50 |
| 17 | Pazopanib | 15.6% | 84.4% | 97.49 |
| 18 | Baricitinib | 15.1% | 84.9% | 97.99 |
| 19 | Dabrafenib | 12.9% | 87.1% | 94.74 |
| 20 | Regorafenib | 9.2% | 90.8% | 95.99 |
| 21 | Tofacitinib | 8.9% | 91.1% | 99.25 |
| 22 | Everolimus | 8.8% | 91.2% | 100.00 |
| 23 | Cabozantinib | 8.7% | 91.3% | 92.73 |
| 24 | Pacritinib | 8.7% | 91.3% | 88.64 |
| 25 | Vemurafenib | 8.3% | 91.7% | 96.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Canertinib | 99.2% | 98.4% | +0.8% |
| Dacomitinib | 97.3% | 99.8% | -2.5% |
| Neratinib | 97.2% | 100.0% | -2.8% |
| Erlotinib | 90.8% | 99.4% | -8.7% |
| Mobocertinib | 88.4% | 100.0% | -11.6% |
| Lapatinib | 69.3% | 99.2% | -29.8% |
| Osimertinib | 61.1% | 99.1% | -38.0% |
| Lazertinib | 53.9% | 100.0% | -46.1% |
| Vandetanib | 51.8% | 99.3% | -47.5% |
| Ibrutinib | 50.9% | 99.3% | -48.5% |
| Fostamatinib | 31.5% | 97.8% | -66.3% |
| Imatinib | 28.4% | — | — |
| Ribociclib | 28.2% | — | — |
| Zanubrutinib | 22.7% | 88.2% | -65.5% |
| Defactinib | 22.6% | 94.6% | -72.0% |
| Trametinib | 17.6% | — | — |
| Pazopanib | 15.6% | — | — |
| Baricitinib | 15.1% | — | — |
| Dabrafenib | 12.9% | — | — |
| Regorafenib | 9.2% | — | — |
| Tofacitinib | 8.9% | — | — |
| Everolimus | 8.8% | — | — |
| Cabozantinib | 8.7% | — | — |
| Pacritinib | 8.7% | — | — |
| Vemurafenib | 8.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.0ms